Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Dundee
With
Almirall Limited
Age
40–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female volunteers aged 40-80 years with moderate to severe COPD (GOLD Stage 2, 3).
On inhaled corticosteroids / long-acting beta agonists
FEV1 30-80% predicted and FEV1/FVC \<70%.
Smoking history ≥10 pack-years.
Ability to give informed consent
Agreement for their General Practitioner to be made aware of study participation and to receive feedback as relevant to the participant's well being
You may not be if
Other respiratory diseases such as asthma, bronchiectasis or allergic bronchopulmonary aspergillosis
A COPD exacerbation or respiratory tract infection requiring systemic steroids and/or antibiotics within 1 month of the study commencement (3 months if hospitalisation has been required)
Any clinically significant medical condition that may endanger the health or safety of the participant
Known or suspected sensitivity to/intolerance of investigational medicinal product
Patients with prostatic hyperplasia, bladder outflow obstruction or glaucoma
Pregnancy or lactation
Unable to comply with the procedures of the protocol
Clareo Health | Evaluation of Long-Acting Muscarinic Antagonists in COPD
